Last 12 months
Inside the activity.
0 purchase rows · 145 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 9 |
| Dec 2025 | 0 | 8 |
| Jan 2026 | 0 | 5 |
| Feb 2026 | 0 | 5 |
| Mar 2026 | 0 | 41 |
| Apr 2026 | 0 | 26 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 9 |
| Jul 2026 | 0 | 11 |
| Aug 2026 | 0 | 11 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 18 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 08, 2020 Filed Jul 11, 2020 00:00 UTC |
Cohen Chad MChief Financial Officer
|
Exercise / conversionStock Option (Right To Buy) · Derivative | 30,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-20-042224 · doc4.xml · derivative · entry 4 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 640,000 Underlying: Common Stock · 30,000 shares Expires 2025-08-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| July 08, 2020 Filed Jul 11, 2020 00:00 UTC |
Cohen Chad MChief Financial Officer
|
SaleCommon Stock | 2,104 | $47.52 | $99,982.08 |
DisclosureSEC source: 0001209191-20-042224 · doc4.xml · nonDerivative · entry 3 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $47.49 to 47.57, inclusive. Read SEC document |
| July 08, 2020 Filed Jul 11, 2020 00:00 UTC |
Cohen Chad MChief Financial Officer
|
SaleCommon Stock | 27,896 | $46.82 | $1,306,090.72 |
DisclosureSEC source: 0001209191-20-042224 · doc4.xml · nonDerivative · entry 2 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,104 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $46.49 to 47.48, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| July 08, 2020 Filed Jul 11, 2020 00:00 UTC |
Cohen Chad MChief Financial Officer
|
Exercise / conversionCommon Stock | 30,000 | $6.32 | $189,600.00 |
DisclosureSEC source: 0001209191-20-042224 · doc4.xml · nonDerivative · entry 1 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019. Read SEC document |
| July 06, 2020 Filed Jul 9, 2020 00:28 UTC |
DOBMEIER ERICDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-20-041832 · doc4.xml · derivative · entry 4 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 10,000 shares Expires 2026-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2020. F4 · derivative.exercise_date: The options vested with respect to 1/4 of the reporting person's shares on September 28, 2017, with an additional 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| July 06, 2020 Filed Jul 9, 2020 00:28 UTC |
DOBMEIER ERICDirector
|
SaleCommon Stock | 400 | $47.98 | $19,192.00 |
DisclosureSEC source: 0001209191-20-041832 · doc4.xml · nonDerivative · entry 3 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $47.83 to 48.42, inclusive. Read SEC document |
| July 06, 2020 Filed Jul 9, 2020 00:28 UTC |
DOBMEIER ERICDirector
|
SaleCommon Stock | 9,600 | $47.34 | $454,464.00 |
DisclosureSEC source: 0001209191-20-041832 · doc4.xml · nonDerivative · entry 2 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $46.80 to 47.70, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| July 06, 2020 Filed Jul 9, 2020 00:28 UTC |
DOBMEIER ERICDirector
|
Exercise / conversionCommon Stock | 10,000 | $6.32 | $63,200.00 |
DisclosureSEC source: 0001209191-20-041832 · doc4.xml · nonDerivative · entry 1 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2020. Read SEC document |
| July 06, 2020 Filed Jul 9, 2020 00:10 UTC |
BALDO LANCEChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 6,250 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001209191-20-041828 · doc4.xml · derivative · entry 4 BALDO LANCE · CIK 0001780773 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 437,500 Underlying: Common Stock · 6,250 shares Expires 2029-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2020. F3 · derivative.exercise_date: The options vested with respect to 1/4 of the shares on May 6, 2020, with 1/48 of the shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| July 06, 2020 Filed Jul 9, 2020 00:10 UTC |
BALDO LANCEChief Medical Officer
|
SaleCommon Stock | 200 | $48.42 | $9,684.00 |
DisclosureSEC source: 0001209191-20-041828 · doc4.xml · nonDerivative · entry 3 BALDO LANCE · CIK 0001780773 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2020. Read SEC document |
| July 06, 2020 Filed Jul 9, 2020 00:10 UTC |
BALDO LANCEChief Medical Officer
|
SaleCommon Stock | 6,050 | $47.29 | $286,104.50 |
DisclosureSEC source: 0001209191-20-041828 · doc4.xml · nonDerivative · entry 2 BALDO LANCE · CIK 0001780773 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $47.00 to 47.83, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| July 06, 2020 Filed Jul 9, 2020 00:10 UTC |
BALDO LANCEChief Medical Officer
|
Exercise / conversionCommon Stock | 6,250 | $7.80 | $48,750.00 |
DisclosureSEC source: 0001209191-20-041828 · doc4.xml · nonDerivative · entry 1 BALDO LANCE · CIK 0001780773 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2020. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 19:00 UTC |
HILL NANCY LOUISEEVP, Operations & Program Mana
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001209191-20-040676 · doc4.xml · derivative · entry 7 HILL NANCY LOUISE · CIK 0001780790 · EVP, Operations & Program Mana 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,000 Underlying: Common Stock · 3,000 shares Expires 2023-11-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2020. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 19:00 UTC |
HILL NANCY LOUISEEVP, Operations & Program Mana
|
SaleCommon Stock | 1,200 | $48.01 | $57,612.00 |
DisclosureSEC source: 0001209191-20-040676 · doc4.xml · nonDerivative · entry 3 HILL NANCY LOUISE · CIK 0001780790 · EVP, Operations & Program Mana 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $47.67 to 48.20, inclusive. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 19:00 UTC |
HILL NANCY LOUISEEVP, Operations & Program Mana
|
SaleCommon Stock | 1,800 | $47.03 | $84,654.00 |
DisclosureSEC source: 0001209191-20-040676 · doc4.xml · nonDerivative · entry 2 HILL NANCY LOUISE · CIK 0001780790 · EVP, Operations & Program Mana 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,200 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $46.66 to 47.59, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 19:00 UTC |
HILL NANCY LOUISEEVP, Operations & Program Mana
|
Exercise / conversionCommon Stock | 3,000 | $0.84 | $2,520.00 |
DisclosureSEC source: 0001209191-20-040676 · doc4.xml · nonDerivative · entry 1 HILL NANCY LOUISE · CIK 0001780790 · EVP, Operations & Program Mana 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2020. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 23:00 UTC |
BENZENO SHARONChief Business Development Off
|
Exercise / conversionCommon Stock (Right to Buy) · Derivative | 1,563 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0001209191-20-040677 · doc4.xml · derivative · entry 8 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,875 Underlying: Common Stock · 1,563 shares Expires 2029-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. F6 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on January 1, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 23:00 UTC |
BENZENO SHARONChief Business Development Off
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,604 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-20-040677 · doc4.xml · derivative · entry 7 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,313 Underlying: Common Stock · 2,604 shares Expires 2028-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on October 1, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 23:00 UTC |
BENZENO SHARONChief Business Development Off
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,604 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-20-040677 · doc4.xml · derivative · entry 6 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,667 Underlying: Common Stock · 2,604 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 23:00 UTC |
BENZENO SHARONChief Business Development Off
|
SaleCommon Stock | 1,200 | $48.13 | $57,756.00 |
DisclosureSEC source: 0001209191-20-040677 · doc4.xml · nonDerivative · entry 5 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $48.03 to 48.20, inclusive. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 23:00 UTC |
BENZENO SHARONChief Business Development Off
|
SaleCommon Stock | 5,571 | $47.17 | $262,784.07 |
DisclosureSEC source: 0001209191-20-040677 · doc4.xml · nonDerivative · entry 4 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,200 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $46.74 to 47.61, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 23:00 UTC |
BENZENO SHARONChief Business Development Off
|
Exercise / conversionCommon Stock | 1,563 | $7.27 | $11,363.01 |
DisclosureSEC source: 0001209191-20-040677 · doc4.xml · nonDerivative · entry 3 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,771 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 23:00 UTC |
BENZENO SHARONChief Business Development Off
|
Exercise / conversionCommon Stock | 2,604 | $6.55 | $17,056.20 |
DisclosureSEC source: 0001209191-20-040677 · doc4.xml · nonDerivative · entry 2 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,208 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 23:00 UTC |
BENZENO SHARONChief Business Development Off
|
Exercise / conversionCommon Stock | 2,604 | $6.55 | $17,056.20 |
DisclosureSEC source: 0001209191-20-040677 · doc4.xml · nonDerivative · entry 1 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. Read SEC document |
| June 26, 2020 Filed Jul 1, 2020 00:25 UTC |
BENZENO SHARONChief Business Development Off
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 417 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-20-039543 · doc4.xml · derivative · entry 3 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 417 Underlying: Common Stock · 417 shares Expires 2026-09-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on July 26, 2017, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| June 26, 2020 Filed Jul 1, 2020 00:25 UTC |
BENZENO SHARONChief Business Development Off
|
SaleCommon Stock | 417 | $47.42 | $19,774.14 |
DisclosureSEC source: 0001209191-20-039543 · doc4.xml · nonDerivative · entry 2 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. Read SEC document |
| June 26, 2020 Filed Jul 1, 2020 00:25 UTC |
BENZENO SHARONChief Business Development Off
|
Exercise / conversionCommon Stock | 417 | $6.32 | $2,635.44 |
DisclosureSEC source: 0001209191-20-039543 · doc4.xml · nonDerivative · entry 1 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 417 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. Read SEC document |
| June 26, 2020 Filed Jul 1, 2020 13:55 UTC |
BENZENO SHARONChief Business Development Off
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 417 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-20-039564 · doc4.xml · derivative · entry 3 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 417 Underlying: Common Stock · 417 shares Expires 2026-09-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on July 26, 2017, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| June 26, 2020 Filed Jul 1, 2020 13:55 UTC |
BENZENO SHARONChief Business Development Off
|
SaleCommon Stock | 417 | $47.42 | $19,774.14 |
DisclosureSEC source: 0001209191-20-039564 · doc4.xml · nonDerivative · entry 2 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. Read SEC document |
| June 26, 2020 Filed Jul 1, 2020 13:55 UTC |
BENZENO SHARONChief Business Development Off
|
Exercise / conversionCommon Stock | 417 | $6.32 | $2,635.44 |
DisclosureSEC source: 0001209191-20-039564 · doc4.xml · nonDerivative · entry 1 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 417 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. Read SEC document |
| June 25, 2020 Filed Jun 26, 2020 00:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 11,100 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-20-039023 · doc4.xml · derivative · entry 13 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,200 Underlying: Common Stock · 11,100 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F9 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| June 25, 2020 Filed Jun 26, 2020 00:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 3,743 | $47.25 | $176,856.75 |
DisclosureSEC source: 0001209191-20-039023 · doc4.xml · nonDerivative · entry 10 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 679 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F8 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $47.11 to 47.48, inclusive. Read SEC document |
| June 25, 2020 Filed Jun 26, 2020 00:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 6,657 | $46.84 | $311,813.88 |
DisclosureSEC source: 0001209191-20-039023 · doc4.xml · nonDerivative · entry 9 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,422 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F7 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $46.11 to 47.10, inclusive. Read SEC document |
| June 25, 2020 Filed Jun 26, 2020 00:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 700 | $45.36 | $31,752.00 |
DisclosureSEC source: 0001209191-20-039023 · doc4.xml · nonDerivative · entry 8 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,079 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F6 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $45.11 to 46.05, inclusive. Read SEC document |
| June 25, 2020 Filed Jun 26, 2020 00:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionCommon Stock | 11,100 | $6.32 | $70,152.00 |
DisclosureSEC source: 0001209191-20-039023 · doc4.xml · nonDerivative · entry 7 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,779 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. Read SEC document |
| June 24, 2020 Filed Jun 25, 2020 20:00 UTC |
Taylor Stacy LSVP and General Counsel
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,771 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-20-039022 · doc4.xml · derivative · entry 5 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,188 Underlying: Common Stock · 1,771 shares Expires 2028-04-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F3 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 12, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| June 24, 2020 Filed Jun 25, 2020 20:00 UTC |
Taylor Stacy LSVP and General Counsel
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,109 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001209191-20-039022 · doc4.xml · derivative · entry 4 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,472 Underlying: Common Stock · 1,109 shares Expires 2029-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on April 23, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| June 24, 2020 Filed Jun 25, 2020 20:00 UTC |
Taylor Stacy LSVP and General Counsel
|
SaleCommon Stock | 2,880 | $46.68 | $134,438.40 |
DisclosureSEC source: 0001209191-20-039022 · doc4.xml · nonDerivative · entry 3 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,300 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. Read SEC document |
| June 24, 2020 Filed Jun 25, 2020 20:00 UTC |
Taylor Stacy LSVP and General Counsel
|
Exercise / conversionCommon Stock | 1,771 | $6.55 | $11,600.05 |
DisclosureSEC source: 0001209191-20-039022 · doc4.xml · nonDerivative · entry 2 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,180 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. Read SEC document |
| June 24, 2020 Filed Jun 25, 2020 20:00 UTC |
Taylor Stacy LSVP and General Counsel
|
Exercise / conversionCommon Stock | 1,109 | $7.80 | $8,650.20 |
DisclosureSEC source: 0001209191-20-039022 · doc4.xml · nonDerivative · entry 1 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,409 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. Read SEC document |
| June 24, 2020 Filed Jun 26, 2020 00:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 11,100 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-20-039023 · doc4.xml · derivative · entry 12 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 411,300 Underlying: Common Stock · 11,100 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F9 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| June 24, 2020 Filed Jun 26, 2020 00:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 2,823 | $46.38 | $130,930.74 |
DisclosureSEC source: 0001209191-20-039023 · doc4.xml · nonDerivative · entry 6 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 679 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F5 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $46.00 to 46.93, inclusive. Read SEC document |
| June 24, 2020 Filed Jun 26, 2020 00:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 8,277 | $45.72 | $378,424.44 |
DisclosureSEC source: 0001209191-20-039023 · doc4.xml · nonDerivative · entry 5 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,502 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $45.14 to 45.99, inclusive. Read SEC document |
| June 24, 2020 Filed Jun 26, 2020 00:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionCommon Stock | 11,100 | $6.32 | $70,152.00 |
DisclosureSEC source: 0001209191-20-039023 · doc4.xml · nonDerivative · entry 4 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,779 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. Read SEC document |
| June 23, 2020 Filed Jun 26, 2020 00:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 11,100 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-20-039023 · doc4.xml · derivative · entry 11 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 422,400 Underlying: Common Stock · 11,100 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F9 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| June 23, 2020 Filed Jun 26, 2020 00:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 9,600 | $46.95 | $450,720.00 |
DisclosureSEC source: 0001209191-20-039023 · doc4.xml · nonDerivative · entry 3 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 679 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $46.46 to 47.36, inclusive. Read SEC document |
| June 23, 2020 Filed Jun 26, 2020 00:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 1,500 | $46.21 | $69,315.00 |
DisclosureSEC source: 0001209191-20-039023 · doc4.xml · nonDerivative · entry 2 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,279 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $45.78 to 46.38, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| June 23, 2020 Filed Jun 26, 2020 00:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionCommon Stock | 11,100 | $6.32 | $70,152.00 |
DisclosureSEC source: 0001209191-20-039023 · doc4.xml · nonDerivative · entry 1 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,779 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. Read SEC document |
| June 22, 2020 Filed Jun 23, 2020 20:00 UTC |
HILL NANCY LOUISEEVP, Operations & Program Mana
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 19,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001209191-20-038660 · doc4.xml · derivative · entry 7 HILL NANCY LOUISE · CIK 0001780790 · EVP, Operations & Program Mana 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,000 Underlying: Common Stock · 19,000 shares Expires 2023-11-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2020. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| June 22, 2020 Filed Jun 23, 2020 20:00 UTC |
HILL NANCY LOUISEEVP, Operations & Program Mana
|
SaleCommon Stock | 14,694 | $45.38 | $666,813.72 |
DisclosureSEC source: 0001209191-20-038660 · doc4.xml · nonDerivative · entry 3 HILL NANCY LOUISE · CIK 0001780790 · EVP, Operations & Program Mana 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $45.00 to 45.54, inclusive. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.